Country: Bandaríkin
Tungumál: enska
Heimild: NLM (National Library of Medicine)
LABETALOL HYDROCHLORIDE (UNII: 1GEV3BAW9J) (LABETALOL - UNII:R5H8897N95)
A-S Medication Solutions
LABETALOL HYDROCHLORIDE
LABETALOL HYDROCHLORIDE 100 mg
ORAL
PRESCRIPTION DRUG
Labetalol hydrochloride tablets, USP are indicated in the management of hypertension. Labetalol hydrochloride tablets, USP may be used alone or in combination with other antihypertensive agents, especially thiazide and loop diuretics. Labetalol hydrochloride tablets are contraindicated in bronchial asthma, overt cardiac failure, greater-than-first-degree heart block, cardiogenic shock, severe bradycardia, other conditions associated with severe and prolonged hypotension, and in patients with a history of hypersensitivity to any component of the product (see WARNINGS ). Beta-blockers, even those with apparent cardioselectivity, should not be used in patients with a history of obstructive airway disease, including asthma.
Product: 50090-1161 NDC: 50090-1161-0 60 TABLET, FILM COATED in a BOTTLE, PLASTIC NDC: 50090-1161-1 90 TABLET, FILM COATED in a BOTTLE, PLASTIC Product: 50090-1290 NDC: 50090-1290-0 100 TABLET, FILM COATED in a BOTTLE, PLASTIC NDC: 50090-1290-1 90 TABLET, FILM COATED in a BOTTLE, PLASTIC Product: 50090-1291 NDC: 50090-1291-0 100 TABLET, FILM COATED in a BOTTLE, PLASTIC NDC: 50090-1291-1 90 TABLET, FILM COATED in a BOTTLE, PLASTIC
Abbreviated New Drug Application
LABETALOL HCL- LABETALOL HYDROCHLORIDE TABLET, FILM COATED A-S MEDICATION SOLUTIONS ---------- LABETALOL HYDROCHLORIDE TABLETS, USP 100 MG, 200 MG AND 300 MG RX ONLY DESCRIPTION Labetalol hydrochloride tablets, USP are adrenergic receptor blocking agents that have both selective alpha -adrenergic and nonselective beta-adrenergic receptor blocking actions in a single substance. Labetalol hydrochloride (HCl) is a racemate chemically designated as 2-hydroxy-5-[1- hydroxy-2-[(1-methyl-3-phenylpropyl) amino] ethyl] benzamide monohydrochloride, and it has the following structure: Labetalol HCl has the molecular formula C H N O •HCl and a molecular weight of 364.9. It has two asymmetric centers and therefore exists as a molecular complex of two diastereoisomeric pairs. Dilevalol, the R, R´stereoisomer, makes up 25% of racemic labetalol. Labetalol HCl is a white or off-white crystalline powder, soluble in water. Labetalol hydrochloride tablets contain 100, 200, or 300 mg of labetalol HCl and are taken orally. The tablets also contain the inactive ingredients lactose monohydrate, corn starch, crospovidone, colloidal silicon dioxide, magnesium stearate, polyvinyl alcohol, polyethylene glycol, titanium dioxide and talc. CLINICAL PHARMACOLOGY Labetalol HCl combines both selective, competitive, alpha -adrenergic blocking and nonselective, competitive, beta-adrenergic blocking activity in a single substance. In man, the ratios of alpha- to beta-blockade have been estimated to be approximately 1:3 1 19 24 2 3 1 and 1:7 following oral and intravenous (IV) administration, respectively. Beta -agonist activity has been demonstrated in animals with minimal beta -agonist (ISA) activity detected. In animals, at doses greater than those required for alpha- or beta-adrenergic blockade, a membrane stabilizing effect has been demonstrated. PHARMACODYNAMICS: The capacity of labetalol HCl to block alpha receptors in man has been demonstrated by attenuation of the pressor effect of phenylephrine and by a significant reduction of the press Lestu allt skjalið